CN118702755A - 神经活性甾类化合物及其使用方法 - Google Patents

神经活性甾类化合物及其使用方法 Download PDF

Info

Publication number
CN118702755A
CN118702755A CN202410694955.5A CN202410694955A CN118702755A CN 118702755 A CN118702755 A CN 118702755A CN 202410694955 A CN202410694955 A CN 202410694955A CN 118702755 A CN118702755 A CN 118702755A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
disorder
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410694955.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·马丁内斯波特拉
B·L·哈里森
A·J·罗比查德
F·G·萨里图罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CN118702755A publication Critical patent/CN118702755A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410694955.5A 2013-03-13 2014-03-13 神经活性甾类化合物及其使用方法 Pending CN118702755A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361779735P 2013-03-13 2013-03-13
US61/779,735 2013-03-13
CN201480026165.4A CN105246486B (zh) 2013-03-13 2014-03-13 神经活性甾类化合物
PCT/US2014/026784 WO2014160480A1 (en) 2013-03-13 2014-03-13 Neuroactive steroids and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480026165.4A Division CN105246486B (zh) 2013-03-13 2014-03-13 神经活性甾类化合物

Publications (1)

Publication Number Publication Date
CN118702755A true CN118702755A (zh) 2024-09-27

Family

ID=51625437

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480026165.4A Active CN105246486B (zh) 2013-03-13 2014-03-13 神经活性甾类化合物
CN202011101409.4A Pending CN112375115A (zh) 2013-03-13 2014-03-13 神经活性甾类化合物及其使用方法
CN202410694955.5A Pending CN118702755A (zh) 2013-03-13 2014-03-13 神经活性甾类化合物及其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201480026165.4A Active CN105246486B (zh) 2013-03-13 2014-03-13 神经活性甾类化合物
CN202011101409.4A Pending CN112375115A (zh) 2013-03-13 2014-03-13 神经活性甾类化合物及其使用方法

Country Status (25)

Country Link
US (6) US20160031930A1 (enExample)
EP (4) EP2968369B1 (enExample)
JP (6) JP6255082B2 (enExample)
CN (3) CN105246486B (enExample)
AU (5) AU2014243773B2 (enExample)
BR (1) BR112015022174B1 (enExample)
CA (2) CA3114062A1 (enExample)
CY (2) CY1120934T1 (enExample)
DK (3) DK2968369T3 (enExample)
ES (3) ES2886506T3 (enExample)
FI (1) FI3932932T3 (enExample)
HR (3) HRP20251221T1 (enExample)
HU (2) HUE055668T2 (enExample)
IL (3) IL280068B2 (enExample)
LT (3) LT3461834T (enExample)
MX (2) MX362544B (enExample)
PL (3) PL2968369T3 (enExample)
PT (3) PT3461834T (enExample)
RS (3) RS58166B1 (enExample)
RU (1) RU2684103C2 (enExample)
SI (3) SI3932932T1 (enExample)
SM (3) SMT202500336T1 (enExample)
TR (1) TR201817995T4 (enExample)
WO (1) WO2014160480A1 (enExample)
ZA (1) ZA201506729B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
CN103329431B (zh) 2010-10-27 2016-09-14 梅鲁斯音频有限公司 使用多电平脉冲宽度调制的音频放大器
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
MX362544B (es) * 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
RU2764702C2 (ru) 2014-10-07 2022-01-19 Сейдж Терапьютикс, Инк. Нейроактивные соединения и способы их применения
PL3319612T3 (pl) * 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
EP3828194B1 (en) * 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HK1255500A1 (zh) * 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) * 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
KR102521573B1 (ko) * 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
TW202444381A (zh) * 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
CN106632565A (zh) * 2016-11-07 2017-05-10 湖南科瑞生物制药股份有限公司 一种合成胆固醇的新方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
EP4072559A4 (en) 2019-12-06 2023-06-21 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
EP4333856A1 (en) * 2021-05-04 2024-03-13 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
US20240368214A1 (en) * 2021-08-25 2024-11-07 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
JP2024534558A (ja) * 2021-09-22 2024-09-20 セージ セラピューティクス， インコーポレイテッド 重水素化ｎｍｄａ正調節化合物及びその使用方法
EP4430056A1 (en) * 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
JP2024544777A (ja) * 2021-12-13 2024-12-04 セージ セラピューティクス， インコーポレイテッド ハンチントン病の治療のための神経活性ステロイド
CN114478672B (zh) * 2022-01-27 2024-06-14 浙江仙居君业药业有限公司 一种he3286的合成方法
CA3260288A1 (en) 2022-06-24 2023-12-28 Sage Therapeutics, Inc. CRYSTALLINE FORMS OF A NEUROACTIVE STEROID
JP2025523826A (ja) 2022-07-12 2025-07-25 セージ セラピューティクス， インコーポレイテッド 神経活性ステロイドの結晶形態
TW202508603A (zh) 2023-05-02 2025-03-01 美商賽吉醫療公司 神經活性類固醇調配物及其使用方法
WO2025227053A1 (en) * 2024-04-25 2025-10-30 Sage Therapeutics, Inc. Nmda receptor positive allosteric modulatory compositions and methods of use thereof

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (enExample) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
ATE45347T1 (de) 1985-05-30 1989-08-15 Taisho Pharmaceutical Co Ltd Vitamin d3-derivate.
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0701444B1 (en) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
PT752860E (pt) * 1994-02-14 2000-12-29 Euro Celtique Sa Androstanos e pregnanos para modulacao alosterica do receptor de gaba
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
CN1171114A (zh) 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
CA2223996A1 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
ATE254628T1 (de) 1995-06-23 2003-12-15 Novo Nordisk As Meiose regulierende verbindungen.
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
CN1326461A (zh) 1998-05-13 2001-12-12 诺沃挪第克公司 减数分裂调控化合物
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
DK1392713T3 (da) * 2001-05-03 2008-02-18 Univ Chicago Lever-X-receptoragonister
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
JP2005508368A (ja) 2001-11-08 2005-03-31 ザ ユニバーシティー オブ シカゴ 高コレステロール濃度に関連した疾患の治療方法
CA2468989A1 (en) 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
NZ547344A (en) 2002-03-27 2007-11-30 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
CA2585471A1 (en) 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
EP2097437B1 (en) 2006-11-21 2015-05-27 Umecrine Cognition AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059239A2 (en) 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
WO2009059961A2 (en) 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
JP2011505357A (ja) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
AU2009206580A1 (en) 2008-01-25 2009-07-30 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
US8778410B2 (en) 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
AR080455A1 (es) * 2010-03-03 2012-04-11 Satori Pharmaceuticals Inc Derivados de esteroides de utilidad para tratar trastornos neurodegenerativos
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
SG2014010417A (en) 2011-10-07 2014-06-27 Takeda Pharmaceutical 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
PT2935307T (pt) 2012-12-18 2018-07-31 Univ Washington Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
EP3309166A3 (en) 2013-01-23 2018-08-22 Sphaera Pharma Pvt. Ltd. 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
MX362544B (es) 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
JP2016514967A (ja) 2013-03-13 2016-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびそれらの使用
SI2986624T1 (sl) 2013-04-17 2020-10-30 Sage Therapeutics, Inc. 19-nor nevroaktivni steroidi za metode zdravljenja
KR102476641B1 (ko) 2014-02-08 2022-12-09 제넨테크, 인크. 알츠하이머병의 치료 방법
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
RU2764702C2 (ru) 2014-10-07 2022-01-19 Сейдж Терапьютикс, Инк. Нейроактивные соединения и способы их применения
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
TW202444381A (zh) 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
AU2018288883B2 (en) 2017-06-23 2022-06-02 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
SG11202004329TA (en) 2017-11-10 2020-06-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders

Also Published As

Publication number Publication date
AU2022279366A1 (en) 2023-01-19
EP3932932B1 (en) 2025-07-16
JP7317898B2 (ja) 2023-07-31
JP7715692B2 (ja) 2025-07-30
JP2022180606A (ja) 2022-12-06
ZA201506729B (en) 2017-09-27
SI3932932T1 (sl) 2025-10-30
TR201817995T4 (en) 2019-02-21
HRP20211300T1 (hr) 2021-11-12
EP2968369A1 (en) 2016-01-20
IL280068B2 (en) 2025-06-01
HUE055668T2 (hu) 2021-12-28
IL318314A (en) 2025-03-01
BR112015022174A2 (pt) 2017-07-18
PL3461834T3 (pl) 2021-12-27
DK3461834T3 (da) 2021-08-23
JP2025120299A (ja) 2025-08-15
IL241301B (en) 2021-01-31
AU2025203021A1 (en) 2025-05-22
IL241301A0 (en) 2015-11-30
CN105246486B (zh) 2020-11-03
HRP20181994T1 (hr) 2019-03-08
JP2018030890A (ja) 2018-03-01
WO2014160480A1 (en) 2014-10-02
AU2014243773B2 (en) 2018-12-13
LT3932932T (lt) 2025-09-10
PL3932932T3 (pl) 2025-11-24
EP3461834B1 (en) 2021-05-19
AU2014243773A1 (en) 2015-10-01
AU2022279366B2 (en) 2025-02-06
RS62235B1 (sr) 2021-09-30
US20170305960A1 (en) 2017-10-26
MX388210B (es) 2025-03-19
HK1220375A1 (en) 2017-05-05
WO2014160480A8 (en) 2015-01-08
SMT202500336T1 (it) 2025-11-10
EP2968369A4 (en) 2016-09-14
RU2019109033A (ru) 2019-05-21
BR112015022174B1 (pt) 2022-07-05
ES2699445T3 (es) 2019-02-11
JP2019135261A (ja) 2019-08-15
US20180237470A1 (en) 2018-08-23
US11104701B2 (en) 2021-08-31
CY1120934T1 (el) 2019-12-11
EP3932932B8 (en) 2025-11-19
EP4643945A2 (en) 2025-11-05
AU2019201275A1 (en) 2019-03-14
JP6255082B2 (ja) 2017-12-27
SI2968369T1 (sl) 2019-01-31
PL2968369T3 (pl) 2019-03-29
RS67266B1 (sr) 2025-10-31
AU2019201275B2 (en) 2020-10-15
CA3114062A1 (en) 2014-10-02
US20160031930A1 (en) 2016-02-04
SMT201800657T1 (it) 2019-01-11
NZ751196A (en) 2020-10-30
CN112375115A (zh) 2021-02-19
US11905309B2 (en) 2024-02-20
RS58166B1 (sr) 2019-03-29
RU2684103C2 (ru) 2019-04-04
PT3932932T (pt) 2025-09-29
EP2968369B1 (en) 2018-08-29
JP2021152086A (ja) 2021-09-30
IL280068B1 (en) 2025-02-01
CA2905359A1 (en) 2014-10-02
EP4643945A8 (en) 2025-12-17
US20220064207A1 (en) 2022-03-03
RU2015143466A (ru) 2017-04-18
MX362544B (es) 2019-01-24
ES3042115T3 (en) 2025-11-18
IL280068A (en) 2021-03-01
DK2968369T3 (en) 2018-12-17
HRP20251221T1 (hr) 2025-12-05
US20240287125A1 (en) 2024-08-29
NZ712141A (en) 2020-10-30
SI3461834T1 (sl) 2021-11-30
BR112015022174A8 (pt) 2019-11-26
JP6530804B2 (ja) 2019-06-12
EP3932932A1 (en) 2022-01-05
CA2905359C (en) 2021-05-25
CY1124629T1 (el) 2022-07-22
EP3461834A1 (en) 2019-04-03
SMT202100475T1 (it) 2021-09-14
LT3461834T (lt) 2021-10-25
HUE072324T2 (hu) 2025-11-28
JP2016513663A (ja) 2016-05-16
AU2021200205A1 (en) 2021-03-18
AU2021200205B2 (en) 2022-09-01
MX2015012430A (es) 2016-02-03
US20190127414A1 (en) 2019-05-02
LT2968369T (lt) 2018-12-27
FI3932932T3 (fi) 2025-10-15
ES2886506T3 (es) 2021-12-20
PT2968369T (pt) 2018-12-05
US10227375B2 (en) 2019-03-12
CN105246486A (zh) 2016-01-13
DK3932932T3 (da) 2025-08-18
PT3461834T (pt) 2021-09-10

Similar Documents

Publication Publication Date Title
JP7317898B2 (ja) 神経刺激性ステロイドおよびその使用方法
RU2808166C2 (ru) Нейроактивные стероиды и способы их применения
HK40066987A (en) Neuroactive steriods and methods of use thereof
HK40007016A (en) Neuroactive steroids
HK40007016B (en) Neuroactive steroids
HK1220375B (en) Neuroactive steroids and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination